Form 10-Q CHARLES RIVER LABORATORI For: Jun 29
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
JPMorgan Downgrades Charles River Labs (CRL) to Neutral
August 8, 2024 5:55 AM EDTJPMorgan analyst Tycho W. Peterson downgraded Charles River Labs (NYSE: CRL) from Overweight to Neutral with a price target of $205.00 (from $270.00).
The analyst comments "As we noted yesterday in our first take, CRL reported a 2Q top- and bottom-line beat (with the latter aided by $0.30 worth of lower bonus accrual benefit) but took down guidance substantially due to an unexpectedly weaker demand environment in DSA. While buyside expectations assumed a guide cut to 2H24 on a slower pace of recovery in biotech within DSA, the magnitude... More
